Nexstim

9.45 EUR

+5.00 %

5,644 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

+5.00 %
+4.30 %
-26.17 %
-33.45 %
-37.21 %
+19.62 %
+152.00 %
+78.30 %
-98.44 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
68.37M EUR
Turnover
64.58K EUR
P/E (adj.) (26e)
67.33
EV/EBIT (adj.) (26e)
58.55
P/B (26e)
13.05
EV/S (26e)
5.56
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.50 EUR
Updated
26.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 27.02.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Viime aikoina useampi kaveri on laittanut huolestuneena viestiä että pitäisikö Nexstimin osakkeet nyt myydä kun kurssi on laskenut niin paljon. Halusin koota yhteen oman kattavan näkemykseni siitä, miksi Nexstim on edelleen ehdottomasti pidemmän tähtäimen omistus. Samalla haluan ...
7 hours ago
by Kyhnykeisari
58
nexstim.com Nexstim - Press-release A press release after a long time
yesterday
by MagnificRat
25
Although sales volumes weren’t staggering at the start of the year, I do believe the Brainlab partnership will already start to show this year. Here is their post regarding the American Association of Neurological Surgeons (AANS) 2026 event. LinkedIn #aans2026 #neurosurgery #spinesurgery...
5/4/2026, 7:12 AM
by AccionHombre
18
@Antti_Siltanen There were 3 trade press releases in Q1, which is as many as there were deliveries. However, the announced and delivered systems are not necessarily the same. 01-05-2026 Nexstim Receives System Order from Distributor in Middle East (Nexstim - Press-release) 02-02-...
4/29/2026, 7:55 AM
by Kyhnykeisari
15
An absolutely fantastic summary, “kyhnykeisari”. One of the best I have ever read on these forums. A BIG THANK YOU. I appreciate it.
5 hours ago
by Taitoo
13
Good summary, thanks @Kyhnykeisari . It’s always good to compile these every now and then. Personally, I’m invested because of point 5 and will re-evaluate the situation after the first published results.
6 hours ago
by AccionHombre
12
Fortunately, some digging reveals an article on Sinaptica’s progress. They raised 9M in an oversubscribed last round and are now heading towards new patient trials starting later this year. The folks at Sinaptica seem very confident, which of course suits us well. They have 5 treatment...
yesterday
by AccionHombre
11
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.